Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bempedoic Acid and Ezetimibe FDC in Type 2 Diabetes and Elevated LDL-C
NCT03531905Phase 2Completed
- Sponsor
- Esperion Therapeutics
- Start
- May 2018
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bempedoic acid in hypercholesterolemia (3 arms), sponsored by Esperion Therapeutics. Primary endpoint: Percent Change From Baseline to Week 12 in Low-density Lipoprotein Cholesterol. Started May 2018; status: completed.
02
Drugs
bempedoic acid
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT03531905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03531905.